Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment.

Autor: Raguz J; Hookipa Pharma Inc, New York, NY, USA., Pinto C; Hookipa Pharma Inc, New York, NY, USA., Pölzlbauer T; Hookipa Pharma Inc, New York, NY, USA., Habbeddine M; Hookipa Pharma Inc, New York, NY, USA., Rosskopf S; Hookipa Pharma Inc, New York, NY, USA., Strauß J; Hookipa Pharma Inc, New York, NY, USA., Just V; Hookipa Pharma Inc, New York, NY, USA., Schmidt S; Hookipa Pharma Inc, New York, NY, USA., Bidet Huang K; Hookipa Pharma Inc, New York, NY, USA., Stemeseder F; Hookipa Pharma Inc, New York, NY, USA., Schippers T; Hookipa Pharma Inc, New York, NY, USA., Stewart E; Vienna BioCenter Core Facilities GmbH (VBCF), Vienna, Austria., Jez J; Vienna BioCenter Core Facilities GmbH (VBCF), Vienna, Austria., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Orlinger KK; Hookipa Pharma Inc, New York, NY, USA., Lauterbach H; Hookipa Pharma Inc, New York, NY, USA Henning.Lauterbach@hookipapharma.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 17; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 17.